Autologous transplant has been in the ICU for a while... thelancet.com/journals/lanha…

Published today in Blood Journal 🎉 Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma #CART #lymsm

Great collaboration with French colleagues Roch Houot Lysa Lymphoma Pere Barba

pubmed.ncbi.nlm.nih.gov/38657242/

5-year follow-up from the LEGEND-2 study of cilta-cel
⏳ 5-year PFS 21% and OS 49% (despite variable LD). 3 progressions after 5 years. No plateau!
🧠No delayed neurotox
🩸No 2nd heme malignancies
🏋️T cells persisted >1 year for VGPR+ (1 at 5.6 years!)
jhoonline.biomedcentral.com/articles/10.11…

Cilta-cel in patients with prior allo SCT in the CARTITUDE-1 study. N=7, ORR: 85.7%. No difference in CRS or ICANS compared to those without prior allo SCT Binod Dhakal #mmsm #bmtsm clinical-lymphoma-myeloma-leukemia.com/article/S2152-…

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of TCE bispecific antibodies in MM #mmsm The Lancet Oncology Paula Rodriguez-Otero Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Jonathan Kaufman, MD Rakesh Popat thelancet.com/journals/lanon…

Cinco de Myeloma (observed)! ! Love celebrating with my UCSF Helen Diller Family Comprehensive Cancer Ctr family! Sandy Wong Ajai Chari Tom Martin JEFFREY WOLF Alfred Chung

Today the FDA Oncologic Drugs Advisory Committee voted 12-0 in favor of using minimal residual disease as an accelerated approval endpoint in multiple myeloma clinical trials.
Meeting info: fda.gov/advisory-commi…
Watch: youtube.com/watch?v=pooME9…

#FDAODAC

Real world data on bridging therapy for CAR-T. Report by U.S. Myeloma Immunotherapy Consortium Aimaz Afrough Yi Lin Surbhi Sidana, MD Gurbakhash Kaur Larry Anderson,MD,PhD,FACP Shonali Midha, M.D. Hamza Hashmi Krina Patel Douglas W. Sborov MD MS Omar Nadeem et al.

nature.com/articles/s4140…

CONGRESS | #EBMT24 | POSTER | Reuben Benjamin King's College London shares the final analysis of the LocoMMotion study in relapsed/refractory #multiplemyeloma .
24-mo PFS 10.5%, 24-mo OS 33.7%, pts treated with a subsequent LOT 61.3%, 79 different regimens were used in subsequent LOT1,

And the vote is in: 12 to 0 .. HUGE step for #mmsm and our patients!!! Leading the way in drug development!!

CONGRESS | #EBMT24 | POSTER | Jordan Schecter Jordan Schecter, MD shares the latest data from the phase III CARTITUDE-4 trial.
At 16-mo mFU ORR 99.4%, ≥CR 86.4%, 12-mo OS 91.9%, PFS 84.9%, MRD neg 71.6%, CRS 76.1%, neurotoxicity 20.5%, ICANS 4.5%.
#mmsm #myeloma The EBMT #TheEBMT

BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms #mmsm #bmtsm nizar jacques bahlis Blood Journal sciencedirect.com/science/articl…

#Myeloma Paper of the Day: CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy, possibly through non-classical monocytes: pubmed.ncbi.nlm.nih.gov/38574299/.

FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple Myeloma onclive.com/view/fda-appro… via @onclive

FDA does another deep dive into causes of early death with cilta-cel.
They note that 'the increased risk of death on the cilta-cel arm appears to persist until at least 5 months and possibly up to 11 months.'

#mmsm FDA Oncology ODAC meeting presenting slides of Sham Mailankody, nice summaries

Available therapies, and summary of trials of NDMM and role of ASCT/maintenance

👀 OS data from CARTITUDE-4 (cilta-cel CAR-T versus #MMsm standard therapies in 1-3 lines).

This is WONDERFUL to see!! Looking forward to hearing the ODAC meeting later this week... and no doubt the manuscript that is in preparation!

We are getting a window into second cancers from CARTITUDE-4 as well from FDA documents. Interestingly, there are 5 (2.7%) heme malignancies in CAR T group but none in the SoC though follow-up is limited.

Below was provided by J&J.
The FDA documents use a shorter cutoff but they do look different, especially for patients with 1 prior line of therapy. FDA also notes some concerns in how the forest plot was generated.

Patients with carotid artery plaque in which microplastics and nanoplastics were detected had a 4 fold higher risk of a composite of myocardial infarction, stroke, or death from any cause at 34 months of follow-up! NEJM
nejm.org/doi/full/10.10…